| Notes to the consolidated annual financial statements l Note 34 |
|
| 34 Taxation paid* |
|
Group |
|
|
Company |
|
|
|
|
|
|
|
| |
|
2017
Rm |
|
|
2016
Rm |
|
|
2017
Rm |
|
|
2016
Rm |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| |
|
(1 181) |
|
|
(288) |
|
|
(666) |
|
|
(52) |
|
| Net tax payable at beginning of year |
|
(640) |
|
|
(341) |
|
|
(653) |
|
|
(344) |
|
| Restatement |
|
– |
|
|
(14) |
|
|
|
|
|
– |
|
| Current taxation |
|
(713) |
|
|
(572) |
|
|
(65) |
|
|
(371) |
|
| Witholding tax |
|
– |
|
|
(1) |
|
|
– |
|
|
– |
|
| Additional payment to SARS |
|
(250) |
|
|
– |
|
|
(251) |
|
|
– |
|
| Acquisition of BCX |
|
– |
|
|
(10) |
|
|
– |
|
|
– |
|
| Interest accrued |
|
(2) |
|
|
10 |
|
|
(2) |
|
|
10 |
|
| Net tax payable at end of year |
|
424 |
|
|
640 |
|
|
305 |
|
|
653 |
|
|
|
|
|
|
|
|
|
|
|
|
|
|
| * |
Included in the 2016 taxation paid is a refund from SARS of R199 million. |
| Notes to the consolidated annual financial statements l Note 34 |
|
|